Figure 2.
Proportions of patients meeting MCID criteria in MEASURE 2 and PREVENT for (a) nocturnal back pain, (b) FACIT-F and (c) morning stiffness.38–40 MEASURE 2: Observed data are presented through week 260. Secukinumab 150 mg, n = 72 and placebo, n = 74; n = 67 and n = 54 at week 16 and 260, respectively, in the secukinumab 150 mg group; n = 64 at week 16 in the placebo group (overall population). Data at week 16 are not statistically significant as no statistical analysis was performed.38 PREVENT: Data presented using non-responder imputation at week 16; presented as observed at week 52. Secukinumab 150 mg loading dose, N = 164 and placebo, N = 171 (anti-TNF-naïve population).33 Pain and morning stiffness at week 52: secukinumab 150 mg loading dose, n = 139; patients switched to open-label secukinumab 150 mg, n = 67. Fatigue at week 52: secukinumab 150 mg loading dose, n = 146; patients switched to open-label secukinumab 150 mg, n = 69.40 MCID definition: nocturnal back pain, defined as an improvement from baseline of ⩾50%; FACIT-F: defined as an improvement from baseline of ⩾4 points; morning stiffness: defined as an improvement from baseline in BASDAI average of ⩾22.5%.40
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MCID, minimum clinically important difference; TNF, tumour necrosis factor.
ap < 0.001 versus placebo.
bp < 0.01 versus placebo.
cp < 0.05 versus placebo.